All In MedTech

Device Trial Radar · NCT07296744

Pivotal Study of the SUpira System in Patients Undergoing High-Risk Percutaneous COronaRy InTervention (HRPCI)

Pivotal Randomized Study of the SUpira System in Patients Undergoing High-Risk Percutaneous COronaRy InTervention (HRPCI)

Last checked: Nov 19, 2026Latest source record: Nov 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingTitle says "pivotal". Randomized with 358 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

358

Planned (sponsor's estimate)

Start

May 11, 2026

Primary completion

Nov 2027

Study completion Nov 2027

Sponsor

Lead sponsor
Supira MedicalNot on our public-company list
Sponsor type
Industry
First posted
Dec 22, 2025

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated device
Yes
Who can join
All sexes, from 18 years, up to 90 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The objective of this study is to assess the safety and efficacy of the Supira System in providing temporary cardiovascular hemodynamic support in patients undergoing HRPCI. Eligible patients will be randomized to undergo HRPCI with either the Supira System (investigational device) or the commercially available Impella systems (comparator device).

Conditions

  • Coronary Artery Disease
  • High Risk Percutaneous Coronary Intervention
  • Interventional Cardiology
  • Mechanical Circulatory Support

Interventions

  • The Supira SystemDevice

    The Supira System is a temporary (≤ 4 hours) ventricular support device indicated for use during elective or urgent HRPCI performed in hemodynamically stable patients with severe coronary artery disease when a heart team has determined HRPCI is the appropriate therapeutic option.

  • ImpellaDevice

    The current commercially available Impella CP with SmartAssist Catheter is indicated for providing temporary (≤ 6 hours) ventricular support during elective or urgent high risk percutaneous coronary i

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Composite Safety and Efficacy OutcomesTime frame: 30 days

Locations

27 sites in 1 country. Site status is shown where the registry gives one.

  • Loma Linda University Medical Center

    Loma Linda, California · Recruiting

  • UC Davis

    Sacramento, California · Recruiting

  • Los Robles Regional Medical Center

    Thousand Oaks, California · Recruiting

24 more study sites with a free account

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.